



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	☒ HHV-8 Infected Cells (BCBL-1)
<b>Catalog Number:</b>	3233
<b>Lot Number:</b>	011288
<b>Release Category:</b>	C
<b>Provided:</b>	1 x 10 <sup>7</sup> cells/ml. Viability is 97%.
<b>Description:</b>	<p>Body cavity based lymphoma cell line found to be infected with HHV-8. Established from a patient with HIV disease and initially presented as an ascites lymphoma. The cell line has undergone single cell cloning. It is not co-infected with EBV.</p> <p>The cells are large, round lymphoma cells that express surface CD38 and CD45, and low levels of CD19.</p>
<b>Special Characteristics:</b>	<p>Cells contain HHV-8 that can be induced into high expression with a phorbol ester. Conditions for stimulation are described in the reference below. Studies of latent HHV-8 genes and those induced into a lytic cycle can be performed similar to those described in the reference.</p> <p>Propagation Medium: RPMI 1640 containing 10 µM 2-mercaptoethanol and 10% FBS.</p> <p>Freeze Medium: Fetal bovine serum, 90%; DMSO, 10%.</p> <p>Growth Characteristics: Start the initial culture at 1 x 10<sup>6</sup> cells/ml. Cells that are growing well in vitro are typically split 1:10 every three to four days. The cells grow as a single cell suspension.</p>
<b>Recommended Storage:</b>	Liquid nitrogen.
<b>Contributor:</b>	Drs. Michael McGrath and Don Ganem

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**References:**

Renne R, Zhong W, Herndier B, Kedes D, McGrath M, Ganem D. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in B cell lymphoma cells in culture. *Nature Med* 2:342-346, 1996.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: BCBL-1 from Drs. Michael McGrath and Don Ganem." Also include the reference cited above in any publications.

**Commercial companies, or those intending to commercialize this reagent, must complete a license before requesting this material. Please contact Dr. Robin Rasor before ordering this reagent through the program: Robin L. Rasor, Director of Licensing, Office of Technology Transfer, The University of Michigan, 3003 S. State Street, Room 2071, Ann Arbor, MI 48109-1280; phone (734) 615-8433; fax: (734) 936-1545; email: [robinlr@umich.edu](mailto:robinlr@umich.edu) ; website: <http://www.techtransfer.umich.edu>**

**Last Updated:**

October 02, 2017

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.